Soap Box, page-19

Always the way with HC isn't it, you post facts from the company's own reports and some bright spark calls you a downramper. Now that something has been released that validates your concern (an AFR article is a huge validation amb) people will probably start telling you you're laying the boot in.

If it comes to it, there are some assets I think ECS should take a look at. The Satipharm and Gelpel stuff maybe for the right price as it would boost IP, perhaps some of their processing equipment also. The facility itself isn't worth anything in my view, anyone who takes it on is just asking for the same thing to happen to themselves.